Global Hemophilia Gene Therapy Market Growth (Status and Outlook) 2023-2029

Global Hemophilia Gene Therapy Market Growth (Status and Outlook) 2023-2029

Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
LPI (LP Information)' newest research report, the “Hemophilia Gene Therapy Industry Forecast” looks at past sales and reviews total world Hemophilia Gene Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Hemophilia Gene Therapy sales for 2023 through 2029. With Hemophilia Gene Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hemophilia Gene Therapy industry.
This Insight Report provides a comprehensive analysis of the global Hemophilia Gene Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hemophilia Gene Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hemophilia Gene Therapy market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hemophilia Gene Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hemophilia Gene Therapy.
The global Hemophilia Gene Therapy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.
This report presents a comprehensive overview, market shares, and growth opportunities of Hemophilia Gene Therapy market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Hemophilia A
Hemophilia B
Segmentation by application
Hemophilia A Gene Therapy
Hemophilia B Gene Therapy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Spark Therapeutics
Ultragenyx
Shire PLC
Sangamo Therapeutics
Bioverativ
BioMarin
uniQure
Freeline Therapeutics

Please note: The report will take approximately 2 business days to prepare and deliver.